The impact of treatment with bile acid sequestrants on quality of life in patients with bile acid diarrhoea
Authors:
Open Access
- 2 July 2022
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-11
Abstract
Background: Bile acid diarrhoea (BAD) can be severely debilitating and negatively affect patients’ quality of life (QoL). We carried out a multi-centre prospective study exploring QoL outcomes in patients with BAD after treatment with colesevelam. Methods: Patients with or without a positive 23-seleno-25-homotaurocholic acid (SeHCAT) scan were recruited and categorised into four groups: SeHCAT negative control group (CG), idiopathic BAD, post-cholecystectomy (PC) and post-terminal ileal resection for Crohn’s disease (CD). Patients with a positive SeHCAT were treated with colesevelam and dosing was titrated to symptomatic response. Patients were reviewed at 4- and 8-weekly intervals and QoL was evaluated by EQ-5D-3L, SF-36, IBDQ-32 at each visit (where relevant). Patients with a negative SeHCAT (CG cohort) completed one set of questionnaires before being discharged from the study. Results: 47 patients (BAD = 24, PC = 12, CD = 11) completed paired QoL questionnaires before and after treatment and 30 CG patients completed a baseline questionnaire. There was a significant improvement in IBDQ-32 mean scores before and after treatment in CD patients [134.6 (95%CI 112.5–156.6) and 158.4 (136.1–180.6), respectively (p = 0.007). Following treatment, BAD patients had significantly improved mean SF-36 scores in the “Role limitation due to physical health” dimension (p = 0.02) and in the overall mental component summary (p = 0.03). Prior to starting treatment, BAD patients had the lowest scores in the ‘activity’ dimension of the EQ-5D-3L (p = 0.04), which improved significantly after treatment (p = 0.002). Overall, the BAD and CD cohort showed improved mean scores with treatment in all components of the SF-36 and EQ-5D-3L, while the PC cohort showed a general decline in mean scores after treatment. 55% of patients clinically responded to treatment of which 41.7%, 58.3% and 81.8% responded from the BAD, PC and CD groups respectively. Correlations between those deemed as responders with improvements on the SF-36 and EQ-5D dimensions were not statistically significant. Conclusion: Our results demonstrate improved QoL in the BAD and CD cohort with treatment. Further larger studies are recommended specifically investigating the PC cohort and whether patients may improve with newer treatments such as FXR agonists. Trial registration Ethical approval REC Ref: 16/LO/1325.Keywords
Funding Information
- Bowel and Cancer Research
- Tillotts Pharma
This publication has 37 references indexed in Scilit:
- Psychiatric, Somatic and Other Functional Gastrointestinal Disorders in Patients With Irritable Bowel Syndrome at a Tertiary Care CenterJournal of Neurogastroenterology and Motility, 2012
- Managing bile acid diarrhoeaTherapeutic Advances in Gastroenterology, 2010
- Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel FunctionClinical Gastroenterology and Hepatology, 2010
- Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2009
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- Prognosis of Adult-Onset Idiopathic Bile Acid MalabsorptionScandinavian Journal of Gastroenterology, 1999
- Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT.Gut, 1994
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990